Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology and impact of exercise training

Journal of Cachexia, Sarcopenia and Muscle

Volumn 6, Issue 3, 2015, Pages 197-207

  Bowen, T Scott ^a   Schuler, Gerhard ^a   Adams, Volker ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cachexia; Exercise training; Molecular analysis; Muscle wasting; Sarcopenia

Indexed keywords

EID: 85062490360     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12043     Document Type: Review

References (150)

1. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–1053.
2. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antago-nism leads to prolonged survival. Cell 2010; 142: 531–543.
3. Carmeli E, Coleman R, Reznick AZ. The bio-chemistry of aging muscle. Exp Gerontol 2002; 37: 477–489.
4. Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab 2013; 20: 1–10.
5. Porter MM, Vandervoort AA, Lexell J. Aging of human muscle: structure, function and adaptability. Scand J Med Sci Sports 1995; 5: 129–142.
6. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.
7. Morley JE, Thomas DR, Wilson MM. Ca-chexia: pathophysiology and clinical rele-vance. Am J Clin Nutr 2006; 83: 735–743.
8. von Haehling S, Anker SD. Prevalence, inci-dence andclinical impact of chaexia: facts and numbers—update 2014. J Cachexia Sarcopenia Muscle 2014; 5: 261–263.
9. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: under-standing the molecular basis. Nat Rev Cancer 2014; 14: 754–762.
10. Husmann I, Soulet L, Gautron J, Martelly I, Barritault D. Growth factors in skeletal muscle regeneration. Cytokine Growth Factor Rev 1996; 7: 249–258.
11. Cassano M, Quattrocelli M, Crippa S, Perini I, Ronzoni F, Sampaolesi M. Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass. J Muscle Res Cell Motil 2009; 30: 243–253.
12. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591–E601.
13. Chrysis D, Underwood LE. Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle of rats made catabolic with dexamethasone. Endocri-nology 1999; 140: 5635–5641.
14. Hong D, Forsberg NE. Effects of serum and insulin-like growth factor I on protein degradation and protease gene expression in rat L8 myotubes. J Anim Sci 1994; 72: 2279–2288.
15. Volpi E, Mittendorfer B, Rasmussen BB, Wolfe RR. The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly. J Clin Endocrinol Metab 2000; 85: 4481–4490.
16. Rasmussen BB, Fujita S, Wolfe RR, Mittendorfer B, Roy M, Rowe VL, et al. Insulin resistance of muscle protein meta-bolism in aging. FASEB J 2006; 20: 768–769.
17. Prisby RD, Ramsey MW, Behnke BJ, Dominguez JM, Donato AJ, Allen MR, et al. Aging reduces skeletal blood flow, endothelium-dependent vasodilation, and no bioavailability in rats. J Bone Miner Res 2007; 22: 1280–1288.
18. Timmerman KL, Lee JL, Fujita S, Dhanani S, Dreyer HC, Fry CS, et al. Pharmacological vasodilation improves insulin-stimulated muscle protein anabolism but not glucose utilization in older adults. Diabetes 2010; 59: 2764–2771.
19. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1a expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA 2009; 106: 20405–20410.
20. Bodine SC, Latres E, Baumhueter S, Lai VKM, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704–1708.
21. Combaret L, Dardevet D, Bechet D, Taillandier D, Mosoni L, Attaix D. Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care 2009; 12: 37–41.
22. DeRuisseau KC, Kavazis AN, Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol 2005; 40: 526–531.
23. Altun M, Besche HC, Overkleeft HS, Piccirillo R, Edelmann MJ, Kessler BM, et al. Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem 2010; 285: 39597–39608.
24. Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margarites I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Ante-rior muscle. Mech Ageing Dev 2006; 127: 794–801.
25. Welle S, Brooks AI, Delehanth JM, Needler N, Thomton CA. Gene expression profile of aging in human muscle. Physiol Genomics 2003; 14: 149–159.
26. Whitman SA, Wacker MJ, Richmond SR, Godard MP. Contributions of the ubiquitin-proteasome pathway and apo-ptosis to human skeletal muscle wasting with age. Pflugers Arch-Eur J Physiol 2005; 450: 437–446.
27. Edström E, Altun M, Hägglund M, Ulfhake B. Atrogin-1/MAFbx and MuRF1 are down-regulated in aging-related loss of skeletal muscle. J Gerontol A Biol Sci Med Sci 2006; 61: 663–674.
28. Attaix D, Mosoni L, Dardevet D, Combaret L, Mirand PP, Grizard J. Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. Int J Biochem Cell Biol 2005; 37: 1962–1973.
29. Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, Ferrington DA. Altered proteasome function and subunit compo-sition in aged muscle. Arch Biochem Biophys 2004; 421: 67–76.
30. Dargelos E, Brule C, Combaret L, Hadj-Sassi A, Dulong S, Poussard S, et al. Involvement of the calcium-dependent proteolytic system in skeletal muscle aging. Exp Gerontol 2007; 42: 1088–1098.
31. Wendt A, Thompson VF, Goll DE. Interac-tion of calpastatin with calpain: a review. Biol Chem 2004; 385: 465–472.
32. Goll DE, Thompson VF, Li H, Wei W, Cong J The calpain system. Physiol Rev 2003; 83: 731–801.
33. Demontis F, Perrimon N. FoxO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell 2010; 143: 813–825.
34. Wohlgemuth SE, Seo AY, Marzetti E, Lees HA, Leeuwenburgh C. Skeletal muscle au-tophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp Gerontol 2010; 45: 138–148.
35. McMullen CA, Ferry AL, Gamboa JL, Andrade FH, Dupont-Versteegden EE. Age-related changes of cell death pathways in rat extraocular muscle. Exp Gerontol 2009; 44: 420–425.
36. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 2013; 45: 2121–2129.
37. Picard M, Ritchie D, Thomas MM, Wright KJ, Hepple RT. Alterations in intrinsic mi-tochondrial function with aging are fiber type-specific and do not explain differen-tial atrophy between muscles. Aging Cell 2011; 10: 1047–1055.
38. Rumsey WL, Kendrick ZV, Starnes JW. Bio-energetics in the aging fischer 344 rat: effects of exercise and food restriction. Exp Gerontol 1987; 22: 271–287.
39. Gouspillou G, Bourdel-Marchasson I, Rouland R, Calmettes G, Biran M, Deschodt-Arsac V, et al. Mitochondrial energetics is impaired in vivo in aged skeletal muscle. Aging Cell 2014; 13: 39–48.
40. Gouspillou G, Bourdel-Marchasson I, Rouland R, Calmettes G, Franconi JM, schodt-Arsac V, et al. Alteration of mi-tochondrial oxidative phosphorylation in aged skeletal muscle involves modifi-cation of adenine nucleotide transloca-tor. Biochim Biophys Acta 2010; 1797: 143–151.
41. Conley KE, Jubrias SA, Esselman PC. Oxi-dative capacity and ageing in human mus-cle. J Physiol 2000; 526: 203–210.
42. Cooper JM, Mann VM, Schapira AHV. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. J Neurol Sci 1992; 113: 91–98.
43. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochon-drial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140–1142.
44. Calvani R, Joseph AM, Adhihetty PJ, Miccheli A, Bossola M, Leeuwenburgh C, et al. Mito-chondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem 2013; 394: 393–414.
45. Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell 2008; 7: 2–12.
46. Rice KM, Blough ER. Sarcopenia-related apoptosis is regulated differently in fast-and slow-twitch muscles of the aging F344/N x BN rat model. Mech Ageing Dev 2006; 127: 670–679.
47. Marzetti E, Wohlgemuth SE, Lees HA, Chung HY, Giovannini S, Leeuwenburgh C. Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mech Ageing Dev 2008; 129: 542–549.
48. Schaap LA, Pluijm SMF, Deeg DJH, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009;64A: 1183–1189.
49. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor ne-crosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002; 57: M326–M332.
50. Rieu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabo-lism and limits sarcopenia in old rats. J Physiol 2009; 587: 5483–5492.
51. Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, et al. Mito-chondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol 2013; 45: 2288–2301.
52. Tedesco FS, Dellavalle A, az-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010; 120: 11–19.
53. Carosio S, Berardinelli MG, Aucello M, Musaro A. Impact of ageing on muscle cell regeneration. Ageing Res Rev 2011; 10: 35–42.
54. Garcia-Prat L, Sousa-Victor P, Munoz-Canoves P. Functional dysregulation of stem cells during aging: a focus on skeletal muscle stem cells. FEBS J 2013; 280: 4051–4062.
55. Sousa-Victor P, Gutarra S, Garcia-Prat L, Rodriguez-Ubreva J, Ortet L, Ruiz-Bonilla V, et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 2014; 506: 316–321.
56. Bernet JD, Doles JD, Hall JK, Kelly Tanaka K, Carter TA, Olwin BB. p38 MAPK signaling underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged mice. Nat Med 2014; 20: 265–271.
57. Collins-Hooper H, Woolley TE, Dyson L, Patel A, Potter P, Baker RE, et al. Age-related changes in speed and mechanism of adult skeletal muscle stem cell migration. Stem Cells 2012; 30: 1182–1195.
58. Collins CA Satellite cell self-renewal. Curr Opin Pharmacol 2006; 6: 301–306.
59. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin nega-tively regulates satellite cell activation and self-renewal. J Cell Bio 2003; 162: 1135–1147.
60. Fry CS, Lee JD, Mula J, Kirby TJ, Jackson JR, Liu F et al. Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. Nat Med 2014; 15 December 2014: doi:10.1038/nm.3710.
61. Sullivan-Gunn MJ, Lewandowski PA. Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase pro-tection are associated with aging sarcopenia. BMC Geriatr 2013; 13: 104.
62. Tanhauser SM, Laipis PJ. Multiple dele-tions are detectable in mitochondrial DNA of aging mice. J Biol Chem 1995; 270: 24769–24775.
63. Bua E, Johnson J, Herbst A, Delong B, McKenzie D, Salamat S, et al. Mitochon-drial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 2006; 79: 469–480.
64. Sakellariou GK, Davis CS, Shi Y, Ivannikov MV, Zhang Y, Vasilaki A, et al. Neuron-specific expression of CuZnSOD prevents the loss of muscle mass and function that occurs in homozygous CuZnSOD-knockout mice. FASEB J 2014; 28: 1666–1681.
65. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129: 227S–237S.
66. Tisdale MJ. Mechanisms of cancer ca-chexia. Physiol Rev 2009; 89: 381–410.
67. Tisdale MJ Molecular pathway leading to cancer cachexia. Physiology 2005; 20: 340–348.
68. Fanzani A, Conraads VM, Penna F, Marti-net W. Molecular and cellular mechanisms of skeletal atrophy: an update. J Cachexia Sarcopenia Muscle 2012; 3: 163–179.
69. von Haehling S, Steinbeck L, Doehner W, Springer J, Anker SD. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol 2013; 45: 2257–2265.
70. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370–378.
71. Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, et al. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J 2013; 27: 2600–2610.
72. Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999; 126: 744–749.
73. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, et al. Increased muscle proteasome activity cor-relates with disease severity in gastric cancer patients. Ann Surg 2003; 237: 384–389.
74. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113: 115–123.
75. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos VE, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a com-mon program of changes in gene expres-sion. FASEB J 2004; 18: 39–51.
76. Forman DE, Daniels KM, Cahalin LP, Zavin A, Allsup K, Cao P, et al. Analysis of skeletal muscle gene expression patterns and the impact of functional capacity in patients with systolic heart failure. J Card Fail 2014; 20: 422–430.
77. Gielen S, Sandri M, Kozarez I, Kratsch J, Teupser D, Thiery J, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) catabolism study. Circulation 2012; 125: 2716–2727.
78. Moreira JBN, Bechara LRG, Bozi LHM, Jannig PR, Monteiro AWA, Dourado PM, et al. High-versus moderate-intensity aerobic exercise training effects on skeletal muscle of infarcted rats. J Appl Physiol 2013; 114: 1029–1041.
79. Wing SS. Deubiquitinases in skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2130–2135.
80. Combaret L, Adegoke OAJ, Bedard N, Baracos V, Attaix D, Wing SS. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab 2005; 288: E693–E700.
81. Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, et al. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 2012; 72: 747–756.
82. Ogawa M, Kariya Y, Kitakaze T, Yamaji R, Harada N, Sakamoto T, et al. The preven-tive effect of ß-carotene on denervation-induced soleus muscle atrophy in mice. Br J Nutr 2013; 109: 1349–1358.
83. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013; 6: 25–39.
84. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M, et al. Au-tophagy is required to maintain muscle mass. Cell Metab 2009; 10: 507–515.
85. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient star-vation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15: 1101–1111.
86. Ceelen JJ, Langen RC, Schols AM. Sys-temic inflammation in chronic obstructive pulmonary disease and lung cancer: com-mon driver of pulmonary cachexia? Curr Opin Support Palliat Care 2014; 8: 339–345.
87. Aucello M, Dobrowolny G, Musaro A. Lo-calized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway. Autophagy 2009; 5: 527–529.
88. Schiaffino S, Hanzlikova V. Studies on the effect of denervation in developing mus-cle. II. The lysosomal system. J Ultrastruct Res 1972; 39: 1–14.
89. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458–471.
90. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458–471.
91. Siu PM, Wang Y, Alway SE. Apoptotic signaling induced by H2O2-mediated oxida-tive stress in differentiated C2C12 myotubes. Life Sci 2009; 84: 468–481.
92. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003; 285: C806–C812.
93. Gomes-Marcondes MC, Tisdale MJ. Induc-tion of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett 2002; 180: 69–74.
94. Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 2012; 131: 2187–2196.
95. Torre-Amione G, Kapadia SR, Benedict C, Oral H, Young JB, Mann DL. Proinflamma-tory cytokine levels in patients with de-pressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201–1206.
96. Kragsbjerg P, Holmberg H, Vikerfors T. Dy-namics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Di 1996; 28: 391–398.
97. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19: 223–248.
98. Fujita J, Tsujinaka T, Ebisui C, Yano M, Shiozaki H, Katsume A, et al. Role of interleukin-6 in skeletal muscle protein breakdown and cathepsin activity in vivo. Eur Surg Res 1996; 28: 361–366.
99. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97: 244–249.
100. Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced ca-chexia. FASEB J 2014; 28: 998–1009.
101. Mangner N, Linke A, Oberbach A, Kullnick Y, Gielen S, Sandri M, et al. Exercise training prevents TNF-a induced loss of force in the diaphragm of mice. PLoS One 2013; 8: e52274.
102. Burney BO, Hayes TG, Smiechowska J, Cardwell G, Papusha V, Bhargava P, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab 2012; 97: E700–E709.
103. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 2006; 75: 19–37.
104. White JP, Gao S, Puppa MJ, Sato S, Welle SL, Carson JA. Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol 2013; 365: 174–186.
105. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phos-phatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005; 280: 2737–2744.
106. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. FoxO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.
107. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1a¦ protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 2006; 103: 16260–16265.
108. Levine S, Biswas C, Dierov J, Barsotti R, Shrager JB, Nguyen T, et al. Increased pro-teolysis, myosin depletion, and atrophic Akt-FoxO signaling in human diaphragm disuse. Am J Respir Crit Care Med 2011; 183: 483–490.
109. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted Akt/FoxO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009; 587: 219–230.
110. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Trans-genic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res 2005; 97: 418–426.
111. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2014; 14: 58–74.
112. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001; 98: 9306–9311.
113. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010; 91: 1123S–1127S.
114. Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in ca-chectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 996–1002.
115. Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol 2012; 60: 1521–1528.
116. Harber MP, Konopka AR, Undem MK, Hinkley JM, Minchev K, Kaminsky LA, et al. Aerobic exercise training induces skeletal muscle hypertrophy and age-dependent adaptations in myofiber function in young and older men. J Appl Phys-iol 2012; 113: 1495–1504.
117. Raue U, Slivka D, Minchev K, Trappe S. Improvements in whole muscle and myocellular function are limited with high-intensity resistance training in octo-genarian women. J Appl Physiol 2009; 106: 1611–1617.
118. Slivka D, Raue U, Hollon C, Minchev K, Trappe S. Single muscle fiber adaptations to resistance training in old (>80 yr) men: evidence for limited skeletal muscle plasticity. Am J Physiol Regul Integr Comp Physiol 2008; 295: R273–R280.
119. Cobley JN, Sakellariou GK, Owens DJ, Murray S, Waldron S, Gregson W, et al. Lifelong training preserves some redox-regulated adaptive responses after an acute exercise stimulus in aged human skeletal muscle. Free Radic Biol Med 2014; 70: 23–32.
120. Pasini E, Le Douairon LS, Flati V, Assanelli D, Corsetti G, Speca S, et al. Effects of treadmill exercise and training frequency on anabolic signaling pathways in the skeletal muscle of aged rats. Exp Gerontol 2012; 47: 23–28.
121. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1a. Cardiovasc Res 2008; 79: 208–217.
122. Lira VA, Brown DL, Lira AK, Kavazis AN, Soltow QA, Zeanah EH, et al. Nitric oxide and AMPK cooperatively regulate PGC-1a in skeletal muscle cells. J Physiol 2010; 588: 3551–3566.
123. Wadley GD, Choate J, McConell GK. NOS isoform-specific regulation of basal but not exercise-induced mitochondrial bio-genesis in mouse skeletal muscle. J Phys-iol 2007; 585: 253–262.
124. Wadley GD, McConell GK. Effect of nitric oxide synthase inhibition on mitochon-drial biogenesis in rat skeletal muscle. J Appl Physiol 2007; 102: 314–320.
125. Konopka AR, Douglass MD, Kaminsky LA, Jemiolo B, Trappe TA, Trappe S, et al. Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J Gerontol A Biol Sci Med Sci 2010; 65: 1201–1207.
126. Martone AM, Lattanzio F, Abbatecola AM, Carpia DL, Tosato M, Marzetti E, et al. Treating sarcopenia in older and oldest old. Curr Pharm Des 2015; 21: 1715–1722.
127. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 2004; 33: 548–555.
128. Moore DR, Atherton PJ, Rennie MJ, Tarnopolsky MA, Phillips SM. Resistance exercise enhances mTOR and MAPK signalling in human muscle over that seen at rest after bolus protein ingestion. Acta Physiol 2011; 201: 365–372.
129. Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exer-cise. J Physiol 2012; 590: 1049–1057.
130. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, et al. A PGC-1a isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 2012; 151: 1319–1331.
131. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases [mdash] myokine regulation. Nat Rev Rheumatol 2015; 11: 86–97.
132. Ikizler TA. Exercise as an anabolic intervention in patients with end-stage renal disease. J Ren Nutr 2011; 21: 52–56.
133. Kosmadakis GC, Bevington A, Smith AC, Clapp EL, Viana JL, Bishop NC, et al. Physical exercise in patients with severe kid-ney disease. Nephron Clin Pract 2010; 115: c7–c16.
134. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment—a systematic review. Crit Rev Oncol/Hematol 2013; 88: 573–593.
135. Gielen S, Adams V, Möbius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart fail-ure. J Am Coll Cardiol 2003; 42: 861–868.
136. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, et al. Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal mus-cle. Circulation 2005; 111: 1763–1770.
137. Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training: molecular mech-anisms. Circulation 2010; 122: 1221–1238.
138. Cunha TF, Bacurau AVN, Moreira JBN, Paixao NA, Campos JC, Ferreira JCB, et al. Exercise training prevents oxidative stress and ubiquitin-proteasome system overac-tivity and reverse skeletal muscle atrophy in heart failure. PLoS One 2012; 7: e41701.
139. Höllriegel R, Beck EB, Linke A, Adams V, Möbius-Winkler S, Mangner N, et al. Ana-bolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int J Cardiol 2013; 167: 975–980.
140. Lenk K, Erbs S, Höllriegel R, Beck E, Linke A, Gielen S, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart fail-ure. Eur J Prev Cardiol 2012; 19: 404–411.
141. Heineke J, uger-Messier M, Xu J, Sargent M, York A, Welle S, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010; 121: 419–425.
142. Hambrecht R, Schulze PC, Gielen S, Linke A, Möbius-Winkler S, Erbs S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2005; 12: 401–416.
143. Toth MJ, Ward K, van der Velden J, Miller MS, VanBuren P, LeWinter MM, et al. Chronic heart failure reduces Akt phos-phorylation in human skeletal muscle: relationship to muscle size and function. J Appl Physiol 2011; 110: 892–900.
144. Gould D, Lahart I, Carmichael A, Koutedakis Y, Metsios G. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle 2013; 4: 111–124.
145. Puppa M, White J, Velezquez K, Baltgalvis K, Sato S, Baynes J, et al. The effect of exercise on IL-6-induced cachexia in the Apc Min/+ mouse. J Cachexia Sarcopenia Muscle 2012; 3: 117–137.
146. Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol 2011; 111: 1190–1198.
147. Toth MJ, Miller MS, VanBuren P, Bedrin NG, LeWinter MM, Ades PA, et al. Resistance training alters skeletal muscle structure and function in human heart failure: effects at the tissue, cellular and molecular levels. J Physiol 2012; 590: 1243–1259.
148. Castaneda C, Gordon PL, Uhlin KL, Levey AS, Kehayias JJ, Dwyer JT, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135: 965–976.
149. Bearne LM, Scott DL, Hurley MV. Exercise can reverse quadriceps sensorimotor dysfunction that is associated with rheuma-toid arthritis without exacerbating disease activity. Rheumatology 2002; 41: 157–166.
150. Roubenoff R, Wilson I. Effect of resistance training on self-reported physical func-tioning in HIV infection. Med Sci Sports Exerc 2001; 33: 1811–1817.